Virus News and Research

Latest Virus News and Research

Janssen submits simeprevir regulatory application in Japan to treat HCV

Medivir AB today announced that its partner Janssen now has submitted a regulatory application to the Japanese Ministry of Health & Welfare authorities seeking approval for simeprevir, administered with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C patients who are treatment naïve, prior non responders or relapsed following treatment with Peg-IFN with or without RBV.

22 Feb 2013

Viewpoints: Holtz-Eakin and Roy offer prescription to fix health law; Iowa lawmakers opposed to Medicaid expansion should give up their coverage

Over nearly a century, progressives have pressed for a national, single-payer healthcare system. When it comes to health reform, what have conservatives stood for? For far too long, conservatives have failed to coalesce around a long-term vision of what a free-market healthcare system should look like. ... Obamacare is the logical byproduct of this conservative policy neglect.

22 Feb 2013

Researchers identify second B-cell attachment receptor for Epstein-Barr virus

Epstein-Barr virus (EBV) affects more than 90 percent of the population worldwide and was the first human virus found to be associated with cancer. Now, researchers from Beth Israel Deaconess Medical Center (BIDMC) have broadened the understanding of this widespread infection with their discovery of a second B-cell attachment receptor for EBV.

21 Feb 2013

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].

21 Feb 2013

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

Sixth death from novel coronavirus recorded in Britain

"A British man infected with a new virus from the same family as SARS has died, health officials said on Tuesday, bringing the worldwide death toll from the previously unknown disease to six," Reuters reports.

21 Feb 2013

Daclatasvir has two primary modes of action against HCV

A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs - within 12 hours of treatment.

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Immunotherapy could be answer to treating novel coronavirus

Investigation into the mechanism of action of the novelcoronavirus HCoV-EMC, which recently emerged in the Middle East, has revealed that although human bronchial epithelia are very susceptible to infection with the virus, interferon I and III were both able to significantly reduce its replication in cell culture.

20 Feb 2013

Healthy adults with shorter telomere length more likely to develop upper respiratory infection

Among healthy adults who were administered a cold virus, those with shorter telomere length (a structure at the end of a chromosome) in certain cells were more likely to develop experimentally-induced upper respiratory infection than participants with longer telomeres, according to results of preliminary research published in the February 20 issue of JAMA.

20 Feb 2013

Working toward polio eradication in 2018

"Since the eradication of smallpox in the late 1970s, no other diseases have followed suit; the goal that has come closest so far is eradication of polio," a Lancet Infectious Diseases editorial states, noting that in 2012 only about 250 people were infected with polio worldwide.

20 Feb 2013

Study may help design better DAA drug cocktails to treat HCV

Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs.

20 Feb 2013

Scientists create new strain of polio to protect vaccine factory workers

"Scientists have created new strains of polio intended to protect workers in factories that make polio vaccine," the New York Times reports.

20 Feb 2013

UCLA plays a vital role in ongoing research into Rasmussen encephalitis

How do you find a cure for a devastating pediatric brain disease so rare that it can take decades to build a meaningful research base? In 2010, the parents of a patient created the Rasmussen Encephalitis (RE) Children's Project to help solve this problem. In a short amount of time, the foundation has raised funds to establish a consortium of top researchers, build a collection of samples of the disease from around the world and support projects to study the disease tissue and search for genetic links. The goal is to find a cure.

20 Feb 2013

New coronavirus could potentially be treated with immunotherapy

The new coronavirus that has emerged in the Middle East is well-adapted to infecting humans but could potentially be treated with immunotherapy, according to a study to be published on February 19 in mBio-, the online open-access journal of the American Society for Microbiology.

20 Feb 2013

SARS-linked virus well adapted to infect humans, could be treated with drugs to boost immune system, study shows

"A new virus that emerged in the Middle East last year and has killed five people is well adapted to infecting humans but could potentially be treated with drugs that boost the immune system, scientists said on Tuesday," Reuters reports, noting, "The virus, called novel coronavirus or NCoV, is from the same family as the common cold and as SARS, or Severe Acute Respiratory Syndrome."

19 Feb 2013

BioCryst fourth quarter revenues decrease to $4.1 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2012.

19 Feb 2013

New lab at Diamond to help scientists delve into inner workings of pathogens

The UK's national synchrotron facility, Diamond Light Source, is now the first and only place in Europe where pathogens requiring Containment Level 3 - including serious viruses such as those responsible for AIDS, Hepatitis and some types of flu - can be analysed at atomic and molecular level using synchrotron light.

18 Feb 2013

Two studies discover new enzyme that acts as a sensor of innate immunity

Two studies by researchers at UT Southwestern Medical Center could lead to new treatments for lupus and other autoimmune diseases and strengthen current therapies for viral, bacterial, and parasitic infections.

16 Feb 2013

Biodiversity in large-scale ecosystems may also provide protection against diseases

The richer the assortment of amphibian species in a pond, the more protection that community of frogs, toads and salamanders has against a parasitic infection that can cause severe deformities, including the growth of extra legs.

16 Feb 2013

Virus News and Research

Latest Virus News and Research

Janssen submits simeprevir regulatory application in Japan to treat HCV

Viewpoints: Holtz-Eakin and Roy offer prescription to fix health law; Iowa lawmakers opposed to Medicaid expansion should give up their coverage

Researchers identify second B-cell attachment receptor for Epstein-Barr virus

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

Sixth death from novel coronavirus recorded in Britain

Daclatasvir has two primary modes of action against HCV

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Immunotherapy could be answer to treating novel coronavirus

Healthy adults with shorter telomere length more likely to develop upper respiratory infection

Working toward polio eradication in 2018

Study may help design better DAA drug cocktails to treat HCV

Scientists create new strain of polio to protect vaccine factory workers

UCLA plays a vital role in ongoing research into Rasmussen encephalitis

New coronavirus could potentially be treated with immunotherapy

SARS-linked virus well adapted to infect humans, could be treated with drugs to boost immune system, study shows

BioCryst fourth quarter revenues decrease to $4.1 million

New lab at Diamond to help scientists delve into inner workings of pathogens

Two studies discover new enzyme that acts as a sensor of innate immunity

Biodiversity in large-scale ecosystems may also provide protection against diseases

A new way of characterising biomolecules eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in